Amantadine and Memantine: Two Distinct NMDA Receptor Antagonists
Amantadine and memantine are both adamantane derivatives that block NMDA receptors, but they have fundamentally different clinical applications: memantine is FDA-approved for moderate to severe Alzheimer's disease dementia, while amantadine is primarily used for Parkinson's disease and has antiviral properties. 1
Mechanism of Action
Both drugs work as uncompetitive NMDA receptor antagonists (also called open-channel blockers), but with critical differences:
Memantine
- Low to moderate affinity NMDA receptor antagonist that binds preferentially to NMDA receptor-operated cation channels 1
- Blocks pathological, chronic low-level activation of NMDA receptors while preserving normal synaptic function due to its fast blocking/unblocking kinetics and strong voltage-dependency 2
- Shows partial trapping - releases from one-sixth of blocked channels rather than being trapped in all of them, allowing some channels to release the blocker between synaptic responses 3
- Does not significantly interact with the CYP450 enzyme system 1
Amantadine
- Also an NMDA receptor antagonist but with different pharmacodynamic properties that affect striatal dopaminergic transmission differently than memantine 4
- Has additional effects on dopamine receptors and dopamine transporter function 4
- Shows complete trapping in NMDA channels, unlike memantine's partial trapping 3
- Has antiviral properties and affects multiple neurotransmitter systems 5
Clinical Applications
Memantine
- FDA-approved for moderate to severe Alzheimer's disease 1
- Improves cognition and global assessment in moderate to severe dementia, though effect sizes may not reach clinically significant thresholds 6
- Can be used as monotherapy or combined with cholinesterase inhibitors like donepezil 6
- Shows benefit in quality of life outcomes for patients with moderate to severe Alzheimer's disease 6
- May benefit REM sleep behavior disorder in Parkinson's disease 7
Amantadine
- Primarily used for Parkinson's disease - not for cognitive enhancement 8
- Used as an antiviral agent 5
- Treats fatigue in Multiple Sclerosis 5
- Does not have significant pro-cognitive effects unlike memantine 8
Key Pharmacological Differences
The critical distinction is that while both are NMDA antagonists, memantine has selective benefits for dementia while amantadine carries notable cognitive risks:
- Memantine improves attention and behavioral symptoms in PD dementia 7
- Extended-release amantadine increases hallucinations and cognitive impairment 7
- Memantine exhibits PCP-like discriminative stimulus effects in animal models, while amantadine does not 9
- Memantine can serve as a reinforcer (suggesting abuse potential at supratherapeutic doses), while amantadine shows minimal reinforcing properties 9
Dosing and Safety
Memantine 1
- Highly absorbed orally with peak concentrations at 3-7 hours
- Terminal elimination half-life: 60-80 hours
- Excreted predominantly unchanged in urine (48%)
- Dose reduction required in severe renal impairment (not mild/moderate)
- Use with caution in severe hepatic impairment
- Common side effects: dizziness, headache, confusion, constipation 1
Amantadine
- Different dopaminergic effects that distinguish it from memantine 4
- Risk of hallucinations and cognitive worsening, particularly with extended-release formulations 7
Clinical Decision-Making
When choosing between these agents, the indication drives the choice:
- For Alzheimer's disease dementia (moderate to severe): Use memantine 6, 10
- For Parkinson's disease motor symptoms: Use amantadine (not memantine for this indication)
- For cognitive symptoms in Parkinson's disease: Consider memantine cautiously; avoid amantadine due to cognitive risks 7
Critical caveat: The evidence shows that benefits of memantine in dementia are modest - only about 9% of patients show global response in excess of placebo 6. Base the decision to use memantine on tolerability, adverse effect profile, ease of use, and cost since head-to-head comparisons are lacking 10. If a beneficial effect occurs, it should be observed within 3 months 10.